Shares of Sucampo Pharmaceuticals Inc. (NASDAQ:SCMP) have earned a consensus recommendation of “Buy” from the eleven brokerages that are currently covering the stock. Five analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $17.75.

A number of research firms have recently commented on SCMP. Zacks Investment Research raised shares of Sucampo Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday, August 8th. Jefferies Group dropped their price target on shares of Sucampo Pharmaceuticals from $16.00 to $14.00 and set a “hold” rating on the stock in a research report on Thursday, August 4th. Maxim Group lifted their price target on shares of Sucampo Pharmaceuticals from $17.00 to $19.00 and gave the company a “buy” rating in a research report on Tuesday. Mizuho lowered shares of Sucampo Pharmaceuticals from a “buy” rating to a “neutral” rating and set a $13.00 price target on the stock. in a research report on Thursday, August 4th. Finally, Vetr lowered shares of Sucampo Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $14.00 price target on the stock. in a research report on Monday, September 19th.

In other Sucampo Pharmaceuticals news, CFO Andrew P. Smith sold 1,766 shares of Sucampo Pharmaceuticals stock in a transaction on Tuesday, November 15th. The shares were sold at an average price of $15.58, for a total transaction of $27,514.28. Following the sale, the chief financial officer now owns 348 shares in the company, valued at $5,421.84. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 3.31% of the company’s stock.

A number of large investors have recently bought and sold shares of SCMP. Zacks Investment Management acquired a new stake in Sucampo Pharmaceuticals during the second quarter worth $110,000. Boothbay Fund Management LLC acquired a new stake in Sucampo Pharmaceuticals during the first quarter worth $114,000. Price T Rowe Associates Inc. MD acquired a new stake in Sucampo Pharmaceuticals during the third quarter worth $129,000. Smith Asset Management Group LP increased its stake in Sucampo Pharmaceuticals by 69.5% in the second quarter. Smith Asset Management Group LP now owns 10,730 shares of the biopharmaceutical company’s stock worth $118,000 after buying an additional 4,400 shares in the last quarter. Finally, Nine Chapters Capital Management LLC acquired a new stake in Sucampo Pharmaceuticals during the third quarter worth $142,000. Hedge funds and other institutional investors own 41.14% of the company’s stock.

Sucampo Pharmaceuticals (NASDAQ:SCMP) opened at 15.375 on Tuesday. The company has a market capitalization of $658.33 million, a P/E ratio of 51.943 and a beta of 1.62. The stock has a 50 day moving average of $12.94 and a 200-day moving average of $11.89. Sucampo Pharmaceuticals has a 52-week low of $9.59 and a 52-week high of $18.75.

Sucampo Pharmaceuticals (NASDAQ:SCMP) last released its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported $0.28 EPS for the quarter, beating the Zacks’ consensus estimate of $0.26 by $0.02. Sucampo Pharmaceuticals had a net margin of 6.29% and a return on equity of 44.19%. The company had revenue of $57.90 million for the quarter, compared to analyst estimates of $51.30 million. During the same quarter last year, the firm posted $0.16 earnings per share. The company’s quarterly revenue was up 73.4% compared to the same quarter last year. On average, equities analysts forecast that Sucampo Pharmaceuticals will post $1.22 earnings per share for the current year.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on research and development of drugs to treat gastrointestinal, ophthalmic and oncology-based inflammatory disorders. It operates through development and commercialization of pharmaceutical products segment. Its operations are conducted through Sucampo AG, based in Zug, Switzerland, through which the Company conducts certain worldwide and European operations; Sucampo Pharma, LLC, based in Tokyo and Osaka, Japan and R-Tech Ueno, Ltd., based in Kobe, Japan, through which the Company conducts its Asian operations; Sucampo Pharma Americas LLC, based in Rockville, Maryland, through which the Company conducts operations in North and South America, and Sucampo Pharma Europe, Ltd., based in Oxford, the United Kingdom.

5 Day Chart for NASDAQ:SCMP

Receive News & Stock Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.